Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Owas Mwape Council Member Data Disclosure in Zambia  MeTA  18/01/10
Type of data being collected <ul><li>Policies, practices and results on </li></ul><ul><ul><li>Registration </li></ul></ul>...
Overview of disclosure process and engagement of stakeholders  <ul><li>How is the data being disclosed?  </li></ul><ul><li...
Challenges & lessons Learned <ul><li>Brief overview of the main challenges </li></ul><ul><li>Bureaucracy </li></ul><ul><li...
Type of support needed <ul><li>Strategies for ensuring full commitment of all stakeholders to the MeTA principle of increa...
Thank you! <ul><li>Owas Mwape </li></ul><ul><li>oramwa@yahoo.com/ </li></ul><ul><li>+260 955 857 161 </li></ul>18/01/10 Me...
Upcoming SlideShare
Loading in …5
×

Data disclosure in Zambia

1,597 views

Published on

Presentation by Owas Mwape, MeTA Zambia Council Member during the country sharing meeting, London 2009.

  • Be the first to comment

  • Be the first to like this

Data disclosure in Zambia

  1. 1. Owas Mwape Council Member Data Disclosure in Zambia MeTA 18/01/10
  2. 2. Type of data being collected <ul><li>Policies, practices and results on </li></ul><ul><ul><li>Registration </li></ul></ul><ul><ul><li>Availability </li></ul></ul><ul><ul><li>Pricing </li></ul></ul><ul><ul><li>Promotion </li></ul></ul>18/01/10 MeTA
  3. 3. Overview of disclosure process and engagement of stakeholders  <ul><li>How is the data being disclosed? </li></ul><ul><li>Data is being disclosed through interviews with key informants in the pharmaceutical sector </li></ul><ul><li>Are the stakeholders involved? How? </li></ul><ul><li>The stakeholders are involved in the process both as data collectors and as key informants </li></ul>18/01/10 MeTA
  4. 4. Challenges & lessons Learned <ul><li>Brief overview of the main challenges </li></ul><ul><li>Bureaucracy </li></ul><ul><li>Unavailability of key informants </li></ul><ul><li>Unavailability of data (publications, etc) </li></ul><ul><li>General suspicion (why is this information being collected) </li></ul><ul><li>General lack of transparency in the medical field (confidentiality seems to apply in the sector) </li></ul><ul><li>Common view that the public lack interest in such matters and therefore there is no need for information to be in the public domain </li></ul><ul><li>What are the lessons learned so far? </li></ul><ul><li>There is need for increased lobbying for full data disclosure in pharmaceutical sector </li></ul><ul><li>Need for full commitment to MeTA principles from stakeholders </li></ul><ul><li>Bureaucracy is still a major challenge!!!! </li></ul>18/01/10 MeTA
  5. 5. Type of support needed <ul><li>Strategies for ensuring full commitment of all stakeholders to the MeTA principle of increased transparency </li></ul><ul><li>MeTA International to advise on how other countries have managed to link up to up to the national health reform process with health summits and joint evaluation </li></ul>18/01/10 MeTA
  6. 6. Thank you! <ul><li>Owas Mwape </li></ul><ul><li>oramwa@yahoo.com/ </li></ul><ul><li>+260 955 857 161 </li></ul>18/01/10 MeTA

×